Indy Hematology Review
Avatar

Allo HSCT: Improvements in Transplant Outcomes, Myeloablative Vs. Reduced-Intensity HCT for AML and MDS, Optimal Haplo Donor

By Indy Hematology Review FEATURING Richard Childs
By Indy Hematology Review FEATURING Richard Childs
0 views
June 26, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
16:18
Masterclasses in Dermatology

Masterclasses from the Wards

Feat. S. Elman
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis
09:42
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…

Feat. M. Al Malki
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
12:15
Moffitt Cancer Center

Using Transplant in Patients With p53 Mutant MDS or AML

Feat. H. Elmariah
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
13:26
Steven Pavletic

Chronic GvHD: Main Complications After ASCT

23:37
Rush University Medical Center

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Feat. E. Bhaimia
44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale
25:38
Rush University Medical Center

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Feat. C. Brunstein